JPH08500084A - 毒素および薬剤を含む治療用複合体 - Google Patents
毒素および薬剤を含む治療用複合体Info
- Publication number
- JPH08500084A JPH08500084A JP5518731A JP51873193A JPH08500084A JP H08500084 A JPH08500084 A JP H08500084A JP 5518731 A JP5518731 A JP 5518731A JP 51873193 A JP51873193 A JP 51873193A JP H08500084 A JPH08500084 A JP H08500084A
- Authority
- JP
- Japan
- Prior art keywords
- complex
- protein
- toxin
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 231100000765 toxin Toxicity 0.000 title claims abstract description 101
- 239000003053 toxin Substances 0.000 title claims abstract description 88
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 229940079593 drug Drugs 0.000 title claims abstract description 67
- 230000001225 therapeutic effect Effects 0.000 title description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 85
- 210000004027 cell Anatomy 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 102000005962 receptors Human genes 0.000 claims abstract description 35
- 108020003175 receptors Proteins 0.000 claims abstract description 35
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 34
- 230000027455 binding Effects 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 244000052769 pathogen Species 0.000 claims abstract description 21
- 230000021615 conjugation Effects 0.000 claims abstract description 19
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 17
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 8
- 108700012359 toxins Proteins 0.000 claims description 83
- 239000000427 antigen Substances 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 58
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 30
- 229920001282 polysaccharide Polymers 0.000 claims description 26
- 150000003077 polyols Chemical group 0.000 claims description 20
- 239000002095 exotoxin Substances 0.000 claims description 18
- 231100000776 exotoxin Toxicity 0.000 claims description 18
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 13
- 230000002163 immunogen Effects 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003638 chemical reducing agent Substances 0.000 claims description 12
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 108010066676 Abrin Proteins 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 9
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 9
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 9
- 108700028325 pokeweed antiviral Proteins 0.000 claims description 9
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 8
- 101710197219 Alpha-toxin Proteins 0.000 claims description 8
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims description 8
- 101710124951 Phospholipase C Proteins 0.000 claims description 8
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 8
- 108010039491 Ricin Proteins 0.000 claims description 8
- 108010084592 Saporins Proteins 0.000 claims description 8
- 239000002776 alpha toxin Substances 0.000 claims description 8
- 229950010131 puromycin Drugs 0.000 claims description 8
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 7
- 102000006382 Ribonucleases Human genes 0.000 claims description 6
- 108010083644 Ribonucleases Proteins 0.000 claims description 6
- 239000007972 injectable composition Substances 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 102000006240 membrane receptors Human genes 0.000 claims description 6
- 108020004084 membrane receptors Proteins 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 244000000010 microbial pathogen Species 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 230000010777 Disulfide Reduction Effects 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000013076 target substance Substances 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 41
- 230000009467 reduction Effects 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 244000045947 parasite Species 0.000 description 10
- 125000002228 disulfide group Chemical group 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- -1 antibodies Proteins 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940127121 immunoconjugate Drugs 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000223104 Trypanosoma Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 241000202889 Mycoplasma salivarium Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000242677 Schistosoma japonicum Species 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 241000203022 Acholeplasma laidlawii Species 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 1
- 241000223838 Babesia bovis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000520674 Mesocestoides corti Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241001137879 Moniezia expansa Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204028 Mycoplasma arginini Species 0.000 description 1
- 241000202956 Mycoplasma arthritidis Species 0.000 description 1
- 241000202894 Mycoplasma orale Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- 235000016594 Potentilla anserina Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 206010047697 Volvulus Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 241000517390 Zuma Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000002725 anti-mycoplasma Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- OATNQHYJXLHTEW-UHFFFAOYSA-N benzene-1,4-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S(O)(=O)=O)C=C1 OATNQHYJXLHTEW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000007647 intestinal volvulus Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 毒素もしくは薬剤と複合したタンパク質であって、該複合体が、薬剤も しくは機能的レセプター結合ドメインを欠いた天然毒素である修飾毒素と、標的 細胞もしくは病原微生物の物質と反応するタンパク質とを含み、該標的物質が該 複合体を細胞もしくは微生物の細胞質内に内在化させ、複合前に該タンパク質が 、複合部位になる少なくとも1個のメルカプト基を有するものである複合タンパ ク質。 2. 上記タンパク質がペプチド、ポリペプチド、ホルモン、リンホカイン、 成長因子、アルブミン、サイトカイン、酵素、免疫調節物質、レセプタータンパ ク質、抗体または抗体フラグメントである請求の範囲第1項に記載の複合タンパ ク質。 3. 上記タンパク質が、複合前にジメルカプトタンパク質を形成するために 還元される少なくとも1個のジスルフィド結合を有する、請求の範囲第1項に記 載の複合タンパク質。 4. 上記ジメルカプトタンパク質が免疫グロブリン、単クローン性抗体また はその特異的結合フラグメントである、請求の範囲第3項に記載の複合タンパク 質。 5. 上記フラグメントがF(ab)2またはF(ab’)2である、請求の範 囲第4項に記載の複合タンパク質。 6. 上記タンパク質がFv、単鎖抗体、FabまたはFab’である、請求 の範囲第1項に記載の複合タンパク質。 7. 上記タンパク質が、リンパ腫、癌腫、肉腫、白血病またはミエローマ上 に存在する腫瘍関連抗原と反応する抗体もしくは抗体フラグメントである、請求 の範囲第1項に記載の複合タンパク質。 8. 上記フラグメントがF(ab)2、F(ab’)2、FabまたはFab ’である、請求の範囲第7項に記載の複合タンパク質。 9. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロニ ン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンであり、 上記薬剤がピューロマイシン、シクロヘキシミドまたはリボヌクレアーゼである 、請求の範囲第1項に記載の複合タンパク質。 10. 上記外毒素が修飾シュードモナス外毒素である、請求の範囲第9項に 記載の複合タンパク質。 11. 免疫原性の少ない複合体を作製するために炭水化物ポリマーまたはポ リオール基と結合させた、請求の範囲第1項に記載の複合タンパク質。 12. 上記炭水化物ポリマーまたはポリオール基が、デキストラン、多糖類 またはポリエチレングリコール(PEG)である、請求の範囲第11項に記載の 複合タンパク質。 13. 上記細胞もしくは病原体の標的物質が膜レセプターである、請求の範 囲第1項に記載の複合タンパク質。 14. 上記標的物質が細胞内抗原またはレセプターである、請求の範囲第1 項に記載の複合タンパク質。 15. 上記標的物質がウイルス抗原またはウイルス誘発抗原である、請求の 範囲第1項に記載の複合タンパク質。 16. 毒素もしくは薬剤と複合した抗体もしくは抗体フラグメントであって 、該複合体が、薬剤もしくは機能的レセプター結合ドメインを欠いた天然毒素で ある修飾毒素と、癌細胞上に存在する腫瘍関連抗原と反応する抗体もしくは抗体 フラグメントとを含み、該抗原が該複合体を癌細胞内に内在化させ、複合前に該 抗体もしくは抗体フラグメントが、複合部位になる少なくとも1個のメルカプト 基を有するものである複合抗体もしくは複合抗体フラグメント。 17. 上記フラグメントがFv、単鎖抗体、Fab、Fab’、F(ab)2 またはF(ab’)2である、請求の範囲第16項に記載の複合体。 18. 上記フラグメントがF(ab)2、F(ab’)2、FabまたはFa b’である、請求の範囲第16項に記載の複合体。 19. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロ ニン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンであり 、上記薬剤がピューロマイシン、シクロヘキシミドまたはリボヌクレアーゼであ る、請求の範囲第16項に記載の複合体。 20. 上記外毒素が修飾シュードモナス外毒素である、請求の範囲第19項 に記載の複合体。 21. 免疫原性の少ない複合体を作製するために炭水化物ポリマーまたはポ リオール基と結合させた、請求の範囲第16項に記載の複合体。 22. 上記炭水化物ポリマーまたはポリオール基が、デキストラン、多糖類 またはポリエチレングリコール(PEG)である、請求の範囲第21項に記載の 複合体。 23. 毒素もしくは薬剤と複合した抗体もしくは抗体フラグメントであって 、該複合体が、薬剤もしくは機能的レセプター結合ドメインを欠いた天然毒素で ある修飾毒素と、標的細胞もしくは病原体に付随する物質と反応する抗体もしく は抗体フラグメントとを含み、該標的細胞もしくは病原体に付随する物質が、該 複合体を該細胞もしくは病原体の細胞質内に内在化させるものであり、該抗体も しくは抗体フラグメントが、毒素もしくは薬剤との複合前に処理されて、重鎖間 のジスルフィド結合が切断され、複合部位になることができる遊離スルフヒドリ ル基を生成するものである、複合抗体または複合抗体フラグメント。 24. 上記フラグメントがFv、単鎖抗体、Fab、Fab’、F(ab)2 またはF(ab’)2である、請求の範囲第23項に記載の複合体。 25. 上記フラグメントがF(ab)2、F(ab’)2、FabまたはFa b’である、請求の範囲第23項に記載の複合体。 26. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロ ニン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンであり 、上記薬剤がピューロマイシン、シクロヘキシミドまたはリボヌクレアーゼであ る、請求の範囲第23項に記載の複合体。 27. 上記外毒素が修飾シュードモナス外毒素である、請求の範囲第26項 に記載の複合体。 28. 免疫原性の少ない複合体を作製するために炭水化物ポリマーまたはポ リオール基と結合させた、請求の範囲第23項に記載の複合体。 29. 上記炭水化物ポリマーまたはポリオール基が、デキストラン、多糖類 またはポリエチレングリコール(PEG)である、請求の範囲第28項に記載の 複合体。 30. 医薬的に許容できる担体中に抗体もしくは抗体フラグメント複合体を 含む組成物の、リンパ腫もしくは白血病をもつ患者の治療方法で使用する医薬の 調製における使用であって、該複合体が、機能的なレセプター結合ドメインを欠 いた天然の毒素である修飾毒素と、リンパ腫もしくは白血病に付随する腫瘍関連 抗原と反応する抗体もしくは抗体フラグメントとを含み、該患者に細胞毒性量の 該医薬を投与し、さらに、該抗原が悪性リンパ腫もしくは白血病細胞内に該複合 体を内在化させるものである該組成物の使用。 31. 上記リンパ腫がB細胞リンパ腫もしくは白血病である、請求の範囲第 30項に記載の使用。 32. 上記抗体フラグメントがFvN単鎖抗体、Fab、Fab’、F(a b)2またはF(ab’)2である、請求の範囲第30項に記載の使用。 33. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロ ニン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンである 、請求の範囲第30項に記載の使用。 34. 上記外毒素が修飾シュードモナス外毒素である、請求の範囲第33項 に記載の使用。 35. 免疫原性の少ない複合体を作製するために炭水化物ポリマーまたはポ リオール基と結合させた、請求の範囲第30項に記載の使用。 36. 上記炭水化物ポリマーまたはポリオール基が、デキストラン、多糖類 またはポリエチレングリコール(PEG)である、請求の範囲第35項に記載の 使用。 37. 上記抗原が膜レセプターである、請求の範囲第30項に記載の使用。 38. 上記抗原が細胞内抗原またはレセプターである、請求の範囲第30項 に記載の使用。 39. 腫瘍によって産生される抗原または腫瘍関連抗原に特異的であるFa b’抗体フラグメントを含む複合体の、癌の治療方法で使用する医薬の製造にお ける使用であって、該フラグメントが機能的なレセプター結合ドメインを欠いた 天然の毒素である修飾毒素と複合されており、該癌の治療が、該抗原を産生する かまたは該抗原と関連する癌をもつヒト患者に非経口的に細胞毒性量の当該医薬 を投与することを含み、該抗原が該癌細胞内に該複合体を内在化させるものであ る該複合体の使用。 40. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロ ニン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンである 、請求の範囲第39項に記載の使用。 41. 上記外毒素が修飾シュードモナス外毒素である、請求の範囲第40項 に記載の使用。 42. 免疫原性の少ない複合体を作製するために炭水化物ポリマーまたはポ リオール基と結合させた、請求の範囲第39項に記載の使用。 43. 上記炭水化物ポリマーまたはポリオール基が、デキストラン、多糖類 またはポリエチレングリコール(PEG)である、請求の範囲第42項に記載の 使用。 44. 上記抗原が膜レセプターである、請求の範囲第39項に記載の使用。 45. 上記抗原が細胞内抗原またはレセプターである、請求の範囲第39項 に記載の使用。 46. (a)抗体複合体もしくは抗体フラグメント複合体であって、該複合 体が、薬剤もしくは機能的レセプター結合ドメインを欠く天然毒素である修飾毒 素と、癌細胞もしくは病原体上に存在する抗原と反応する抗体もしくは抗体フラ グメントとを含み、該抗原が該複合体を該細胞もしくは病原体内に内在化させる ものである複合抗体もしくは複合抗体フラグメント、および(b)医薬的に許容 できる注射用賦形剤を含む、殺菌済み注射可能組成物。 47. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロ ニン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンである 、請求の範囲第46項に記載の組成物。 48. (a)機能的なレセプター結合ドメインを欠く天然毒素である修飾毒 素と、標的細胞もしくは病原体の物質と反応するタンパク質とを含む、毒素と複 合したタンパク質、および(b)医薬的に許容できる注射用賦形剤を含む殺菌済 み注射可能組成物であって、該標的細胞もしくは病原体の物質が該複合体を細胞 の細胞質内に内在化させるものであり、複合前に該タンパク質が、複合のための 部位となる少なくとも1個のメルカプト基を有するものである無菌的注射可能組 成物。 49. 上記タンパク質がペプチド、ポリペプチド、ホルモン、リンホカイン 、成長因子、アルブミン、サイトカイン、酵素、免疫調節物質、レセプタータン パ ク質、抗体または抗体フラグメントである、請求の範囲第48項に記載の組成物 。 50. 上記タンパク質が免疫グロブリン、単クローン性抗体またはその特異 的結合フラグメントである、請求の範囲第48項に記載の組成物。 51. 上記タンパク質が抗体フラグメントである請求の範囲第50項に記載 の組成物。 52. 上記フラグメントがF(ab)2またはF(ab’)2である、請求の 範囲第51項に記載の組成物。 53. 上記フラグメントがFv、単鎖抗体、FabまたはFab’である、 請求の範囲第51項に記載の組成物。 54. 上記タンパク質か、リンパ腫もしくは白血病細胞上に存在する腫瘍関 連抗原と反応する抗体もしくは抗体フラグメントである、請求の範囲第48項に 記載の組成物。 55. 上記タンパク質が、癌細胞上に存在する腫瘍関連抗原と反応する抗体 もしくは抗体フラグメントである、請求の範囲第48項に記載の組成物。 56. 上記タンパク質か、病原体に付随する抗原と反応する抗体もしくは抗 体フラグメントである、請求の範囲第48項に記載の組成物。 57. 上記病原体がウイルス、原虫または細菌である、請求の範囲第56項 に記載の組成物。 58. 上記フラグメントがF(ab)2、F(ab’)2、FabまたはFa b’である、請求の範囲第54項に記載の組成物。 59. 上記毒素がアブリン、アルファ毒素、ジフテリア毒素、外毒素、ゲロ ニン、アメリカヤマゴボウ抗ウイルスタンパク質、リシンまたはサポリンであり 、上記薬剤がピューロマイシン、シクロヘキシミドまたはリボヌクレアーゼであ る、請求の範囲第48項に記載の組成物。 60. 上記外毒素が修飾シュードモナス外毒素である、請求の範囲第59項 に記載の組成物。 61. 免疫原性の少ない複合体を作製するために炭水化物ポリマーまたはポ リオール基と結合させた、請求の範囲第48項に記載の組成物。 62. 上記炭水化物ポリマーまたはポリオール基が、デキストラン、多糖類 またはポリエチレングリコール(PEG)である、請求の範囲第61項に記載の 組成物。 63. 上記抗原が膜レセプターである、請求の範囲第48項に記載の組成物 。 64. 上記抗原が細胞内抗原またはレセプターである、請求の範囲第48項 に記載の組成物。 65. 上記抗原がウイルス抗原またはウイルス誘発抗原である、請求の範囲 第48項に記載の組成物。 66.薬剤もしくは機能的なレセプター結合ドメインを欠いた毒素と、少なく とも1個のジスルフィド結合を有するタンパク質前駆体由来のタンパク質とを含 む複合体の調製方法であって、 (a)該タンパク質前駆体をジスルフィド還元剤と反応させ、ジメルカプトタン パク質を生成し、 (b)該毒素もしくは薬剤と該ジメルカプトタンパク質とを接触させて該複合体 を生成する工程を含む該複合体の調製方法。 67. 上記タンパク質前駆体がペプチド、ポリペプチド、ホルモン、リンホ カイン、成長因子、アルブミン、サイトカイン、酵素、免疫調節剤、レセプター タンパク質、抗体または抗体フラグメントである、請求の範囲第66項に記載の 方法。 68. 上記タンパク質前駆体が免疫グロブリン、単クローン性抗体、多クロ ーン性抗体、またはその特異的結合フラグメントである、請求の範囲第66項に 記載の方法。 69. 抗体フラグメントかF(ab)2、F(ab’)2、FabまたはFa b’である請求の範囲第66項に記載の方法。 70. 上記ジメルカプトタンパク質が上記毒素との接触前に安定化されてい る請求の範囲第66項に記載の方法。 71. 上記ジメルカプトタンパク質が凍結乾燥によって安定化されている請 求の範囲第69項に記載の方法。 72. Fab’抗体フラグメントと、機能的なレセプター結合ドメインを欠 いた薬剤もしくは毒素とを含む複合体の製造方法であって、 (a)複数の基部遊離スルフヒドリル基を生じるために十分な量であるが、該抗 体を免疫学的に不活性にするには不十分な量の、ジスルフィド複合体を切断する ための還元剤で、無傷の抗体を部分的に還元し、さらに該部分的に還元された抗 体を回収し、 (b)該部分的に還元された抗体を切断して、還元されたF(ab’)2フラグ メントを生じさせ、 (c)該部分的に還元されたF(ab’)2フラグメントの溶液を機能的な結合 ドメインを欠く毒素もしくは薬剤と接触させる工程を含む該複合体の製造方法。 73. (a)少なくとも1個の付属スルフヒドリル基を有するタンパク質と 、(b)機能的なレセプター結合ドメインを欠く毒素もしくは薬剤との混合物を 、溶液中で接触させ、生じた複合体の溶液を回収する工程を含む、タンパク質と 毒素もしくは薬剤の複合体の製造方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US882,177 | 1992-05-11 | ||
US07/882,177 | 1992-05-11 | ||
US07/882,177 US5541297A (en) | 1988-04-01 | 1992-05-11 | Therapeutic conjugates of toxins and drugs |
PCT/US1993/004136 WO1993023062A1 (en) | 1992-05-11 | 1993-05-07 | Therapeutic conjugates of toxins and drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08500084A true JPH08500084A (ja) | 1996-01-09 |
JP2942356B2 JP2942356B2 (ja) | 1999-08-30 |
Family
ID=25380048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5518731A Expired - Fee Related JP2942356B2 (ja) | 1992-05-11 | 1993-05-07 | 毒素および薬剤を含む治療用複合体 |
Country Status (10)
Country | Link |
---|---|
US (2) | US5541297A (ja) |
EP (2) | EP1283059A3 (ja) |
JP (1) | JP2942356B2 (ja) |
AT (1) | ATE248858T1 (ja) |
CA (1) | CA2118032C (ja) |
DE (1) | DE69333182T2 (ja) |
DK (1) | DK0651646T3 (ja) |
ES (1) | ES2208639T3 (ja) |
PT (1) | PT651646E (ja) |
WO (1) | WO1993023062A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508954A (ja) * | 2002-11-13 | 2006-03-16 | ブラッコ イメージング ソチエタ ペル アチオニ | 免疫グロブリンfabフラグメントを選択的且つ定量的に官能基化する方法,並びにそれにより得られる結合化合物及びその組成物 |
WO2008146854A1 (ja) * | 2007-05-28 | 2008-12-04 | National Institute Of Advanced Industrial Science And Technology | 抗モータリン抗体のパラトープ及びエピトープ |
JP2009136275A (ja) * | 2007-05-28 | 2009-06-25 | National Institute Of Advanced Industrial & Technology | 抗モータリン抗体のパラトープ及びエピトープ |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
WO1994002174A1 (en) * | 1992-07-28 | 1994-02-03 | Toray Industries, Inc. | Immunocomplex |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
US6083477A (en) * | 1996-10-17 | 2000-07-04 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
AU5910998A (en) * | 1997-01-13 | 1998-08-03 | Emory University | Compounds and their combinations for the treatment of influenza infection |
US6090381A (en) | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
US6251866B1 (en) | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
EP1011705A4 (en) * | 1997-08-05 | 2000-09-20 | Watson Pharmaceuticals Inc | CONJUGATES TARGETED AT THE INTERLEUKIN-2 RECEPTOR |
AU3916397A (en) * | 1997-08-15 | 1999-03-08 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting tp-3/p80 |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
DK1346731T3 (da) * | 1998-07-22 | 2007-04-10 | Osprey Pharmaceuticals Ltd | Konjugater til behandling af inflammatoriske forstyrrelser og tilsvarende vævsskade |
AU2007201755B2 (en) * | 1998-07-22 | 2007-09-20 | Osprey Pharmaceuticals Usa, Inc. | Conjugates for treating inflammatory disorders and associated tissue damage |
US6998106B1 (en) | 1998-12-01 | 2006-02-14 | Duke University | Radioconjugation of internalizing antibodies |
AU2002332637A1 (en) * | 2001-08-22 | 2003-03-10 | Watson Pharmaceuticals, Inc. | Conjugates targeted to target receptors |
US7053188B2 (en) | 2002-02-22 | 2006-05-30 | Purdue Research Foundation | Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
US20060024289A1 (en) * | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) * | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
WO2004085505A2 (en) * | 2003-03-24 | 2004-10-07 | Sequoia Pharmaceuticals, Inc. | Long acting biologically active conjugates |
US8394379B2 (en) * | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
US8703134B2 (en) | 2003-05-15 | 2014-04-22 | Iogenetics, Llc | Targeted cryptosporidium biocides |
US7566447B2 (en) | 2003-05-15 | 2009-07-28 | Iogenetics, Llc | Biocides |
US20050014932A1 (en) * | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US20050059101A1 (en) * | 2003-09-10 | 2005-03-17 | Gordon Ringold | Bivalent targeting of cell surfaces |
US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
DK2447375T3 (da) | 2004-03-31 | 2019-07-29 | Massachusetts Gen Hospital | Fremgangsmåde til bestemmelse af responsiviteten af en tumor på behandlinger med den epidermale vækstfaktor-receptor som mål |
DK1735439T3 (da) | 2004-04-12 | 2012-02-06 | Catalyst Biosciences Inc | Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1 |
US20050247330A1 (en) * | 2004-04-30 | 2005-11-10 | Hp Intellectual Corp. | Liquid presence sensor |
US20060018827A1 (en) * | 2004-07-08 | 2006-01-26 | Ekaterina Dadachova | Positron therapy of inflammation, infection and disease |
EP1812550A2 (en) * | 2004-10-20 | 2007-08-01 | Iogenetics, Llc | Biocides |
CA2549663A1 (en) * | 2005-06-06 | 2006-12-06 | University Of Northern British Columbia | Endoribonuclease and uses thereof |
EP2674440B1 (en) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
ES2372709T3 (es) | 2006-07-05 | 2012-01-25 | Catalyst Biosciences, Inc. | Procedimientos de cribado de proteasas y proteasas identificadas por los mismos. |
JP2008111824A (ja) * | 2006-09-01 | 2008-05-15 | Nox Technologies Inc | 腫瘍特異的tNOXアイソフォーム及び方法 |
EP2184608B1 (en) * | 2007-08-23 | 2016-10-05 | LSI Medience Corporation | Non-specific reaction inhibitor |
WO2010014117A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
DK3912643T3 (da) | 2009-02-13 | 2022-10-17 | Immunomedics Inc | Immunokonjugater med en intracellulært-spaltelig binding |
AU2011210825B2 (en) | 2010-01-27 | 2017-02-02 | Children's Medical Center Corporation | Pro-angiogenic fragments of prominin-1 and uses thereof |
US9745631B2 (en) | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
EP3560509B1 (en) | 2011-12-22 | 2024-01-31 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
EP2855698A4 (en) | 2012-05-24 | 2016-03-30 | Dana Farber Cancer Inst Inc | TARGETING THE PATHWAY FROM GLUTAMINE TO PYRUVATE TO TREAT CANCER ASSOCIATED WITH ONCOGEN KRAS |
WO2014014518A1 (en) | 2012-07-18 | 2014-01-23 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
US10130590B2 (en) | 2013-10-01 | 2018-11-20 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
EP3122369B1 (en) | 2014-03-26 | 2022-08-31 | Children's Medical Center Corporation | Cyclic prosaposin peptides and uses thereof |
US10350264B2 (en) | 2014-03-27 | 2019-07-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin |
AU2017283653C1 (en) | 2016-06-16 | 2022-05-05 | Oncoselect Therapeutics, Llc | Porphyrin compounds and compositions useful for treating cancer |
SG11202003893UA (en) | 2017-12-29 | 2020-05-28 | Ap Biosciences Inc | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US4698420A (en) * | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
DE3617430A1 (de) * | 1986-05-23 | 1987-11-26 | Merck Patent Gmbh | Perlglanzpigmente |
EP0315456B1 (en) * | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
DE3873887T2 (de) * | 1987-12-02 | 1993-02-04 | Neorx Corp | Spaltbare immun-conjugate fuer die abgabe und freisetzung von agenzien in natuerlicher form. |
US5061641A (en) * | 1988-04-01 | 1991-10-29 | Immunomedics, Inc. | Method for radiolabeling proteins |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
-
1992
- 1992-05-11 US US07/882,177 patent/US5541297A/en not_active Expired - Lifetime
-
1993
- 1993-05-07 DE DE69333182T patent/DE69333182T2/de not_active Expired - Lifetime
- 1993-05-07 ES ES93910988T patent/ES2208639T3/es not_active Expired - Lifetime
- 1993-05-07 JP JP5518731A patent/JP2942356B2/ja not_active Expired - Fee Related
- 1993-05-07 AT AT93910988T patent/ATE248858T1/de not_active IP Right Cessation
- 1993-05-07 DK DK93910988T patent/DK0651646T3/da active
- 1993-05-07 PT PT93910988T patent/PT651646E/pt unknown
- 1993-05-07 WO PCT/US1993/004136 patent/WO1993023062A1/en active IP Right Grant
- 1993-05-07 CA CA002118032A patent/CA2118032C/en not_active Expired - Lifetime
- 1993-05-07 EP EP02079619A patent/EP1283059A3/en not_active Withdrawn
- 1993-05-07 EP EP93910988A patent/EP0651646B1/en not_active Expired - Lifetime
-
1995
- 1995-05-26 US US08/452,131 patent/US5601825A/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508954A (ja) * | 2002-11-13 | 2006-03-16 | ブラッコ イメージング ソチエタ ペル アチオニ | 免疫グロブリンfabフラグメントを選択的且つ定量的に官能基化する方法,並びにそれにより得られる結合化合物及びその組成物 |
JP2011148820A (ja) * | 2002-11-13 | 2011-08-04 | Bracco Imaging Spa | 免疫グロブリンfabフラグメントを選択的且つ定量的に官能基化する方法 |
WO2008146854A1 (ja) * | 2007-05-28 | 2008-12-04 | National Institute Of Advanced Industrial Science And Technology | 抗モータリン抗体のパラトープ及びエピトープ |
JP2009136275A (ja) * | 2007-05-28 | 2009-06-25 | National Institute Of Advanced Industrial & Technology | 抗モータリン抗体のパラトープ及びエピトープ |
US8591893B2 (en) | 2007-05-28 | 2013-11-26 | National Institute Of Advanced Industrial Science And Technology | Paratope and epitope of anti-mortalin antibody |
Also Published As
Publication number | Publication date |
---|---|
CA2118032A1 (en) | 1993-11-25 |
EP0651646A1 (en) | 1995-05-10 |
PT651646E (pt) | 2003-12-31 |
JP2942356B2 (ja) | 1999-08-30 |
EP0651646B1 (en) | 2003-09-03 |
EP1283059A3 (en) | 2004-01-02 |
DE69333182T2 (de) | 2004-07-15 |
ATE248858T1 (de) | 2003-09-15 |
ES2208639T3 (es) | 2004-06-16 |
DE69333182D1 (de) | 2003-10-09 |
US5541297A (en) | 1996-07-30 |
US5601825A (en) | 1997-02-11 |
EP0651646A4 (en) | 1997-07-09 |
WO1993023062A1 (en) | 1993-11-25 |
EP1283059A2 (en) | 2003-02-12 |
DK0651646T3 (da) | 2003-10-13 |
CA2118032C (en) | 1998-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08500084A (ja) | 毒素および薬剤を含む治療用複合体 | |
KR860001803B1 (ko) | 이뮤노톡신 결합체의 제조방법 | |
AU745823B2 (en) | Immunotoxins, comprising an onc protein, directed against malignant cells | |
CA2651285C (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
JPH10506881A (ja) | 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物 | |
US20200140538A1 (en) | Anti-human interleukin-2 antibodies and uses thereof | |
EP1045861B1 (en) | Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit | |
Embleton | Drug-targeting by monoclonal antibodies. | |
US5690935A (en) | Biotherapy of cancer by targeting TP-3/P80 | |
EP1351709B1 (en) | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates | |
AU2001269762A1 (en) | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates | |
JPH04506217A (ja) | 免疫結合体による感染症の検出と治療 | |
Trail et al. | Site‐directed delivery of anthracyclines for treatment of cancer | |
EP1085908B1 (en) | Recombinant immunotoxin directed against the hiv-1 gp120 envelope glycoprotein | |
CA1338818C (en) | Immunotoxins | |
JP2648317B2 (ja) | Fcレセプターに対するモノクローナル抗体 | |
JPH0428720B2 (ja) | ||
Edwards et al. | Antibody-toxin conjugates as potential therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090618 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100618 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100618 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110618 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120618 Year of fee payment: 13 |
|
LAPS | Cancellation because of no payment of annual fees |